Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Therapeutic HPV Vaccine (BNT113) Trial in HPV16 Driven Carcinoma

Next Previous
Trial Profile

Therapeutic HPV Vaccine (BNT113) Trial in HPV16 Driven Carcinoma

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 08 Nov 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs BNT 113 (Primary)
  • Indications Anal cancer; Carcinoma; Cervical cancer; Head and neck cancer; Penile cancer; Squamous cell cancer; Urogenital cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms HARE-40

Most Recent Events

  • 04 Nov 2024 According to a BioNTech media release, In September 2024, at ESMO, results were presented from an investigator-sponsored Phase 1/2 dose escalation clinical trial evaluating BNT113 alone in the post-adjuvant and metastatic settings in patients with HPV16+ head and neck and other cancers. BNT113 was shown to induce immune responses in patients in the adjuvant and end-stage clinical settings and to be overall well tolerated with a manageable safety profile.
  • 05 Aug 2024 According to a BioNTech media release, data from this study will be presented in at the 2024 Congress of the European Society of Medical Oncology taking place from September 13-17, 2024 in Barcelona, Spain.
  • 02 Feb 2024 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top